Trial Profile
Study of Anti-CD19 Chimeric Antigen Receptor T CellsPZ01 for Relapsed/ Refractory B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs PZ 01 (Primary)
- Indications B-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms 2017002
- 27 Jul 2017 New trial record